TriSalus director Sean Murphy resigns from board

TriSalus Life Sciences, Inc. reported that board member Sean Murphy resigned from the company’s Board of Directors and its Science and Technology Committee, effective September 30, 2025.

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. reported that board member Sean Murphy resigned from the company’s Board of Directors and its Science and Technology Committee, effective September 30, 2025. The company stated that his resignation is not due to any disagreement with TriSalus on its operations, policies, or practices. The filing confirms the change is limited to his board and committee roles and provides no indication of broader operational or strategic issues.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TriSalus Life Sciences (TLSI) disclose in this 8-K?

The company disclosed that Sean Murphy resigned from its Board of Directors and the Science and Technology Committee, effective September 30, 2025.

Why did Sean Murphy resign from the TriSalus (TLSI) board?

The company stated that Mr. Murphy’s resignation was not the result of any disagreement with TriSalus regarding its operations, policies, or practices.

Which roles did Sean Murphy leave at TriSalus Life Sciences?

He resigned from his position as a member of the Board of Directors and from the Science and Technology Committee of the Board.

When did the TriSalus (TLSI) director resignation become effective?

Sean Murphy’s resignation became effective immediately on September 30, 2025.

Does the filing indicate any issues or disputes at TriSalus Life Sciences?

The company explicitly stated that Mr. Murphy’s resignation is not due to any disagreement on matters related to TriSalus’ operations, policies, or practices.

What stock and warrants does TriSalus Life Sciences (TLSI) list on Nasdaq?

TriSalus lists its common stock under the symbol TLSI and its warrants, each exercisable for one share at an exercise price of $11.50, under the symbol TLSIW on the Nasdaq Global Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/01/2025 - 04:28 PM Learn about SEC filing dates

0001826667FALSE00018266672025-09-302025-09-300001826667us-gaap:CommonStockMember2025-09-302025-09-300001826667us-gaap:WarrantMember2025-09-302025-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2025

TRISALUS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-39813			85-3009869
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)
6272 W 91st Ave, Westminster, Colorado						80031
(Address of principal executive office)						(Zip Code)

(888) 321-5212

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.0001 par value			TLSI			Nasdaq Global Market
Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share			TLSIW			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02						Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers.
(b)

On September 30, 2025, Sean Murphy informed the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) of his decision to resign from his position as a member of the Board and the Science and Technology Committee of the Board, effective immediately. Mr. Murphy’s resignation is not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 1, 2025			TriSalus Life Sciences, Inc.
			By:			/s/ David Patience
						Name:			David Patience
						Title:			Chief Financial Officer